Urolithin A mitigated doxorubicin-induced myocardial injury by inhibiting ROS-driven apoptosis both in vitro and in vivo.
Does Urolithin A mitigate doxorubicin-induced myocardial injury in preclinical models?
Urolithin A demonstrates preclinical potential to protect against doxorubicin-induced cardiotoxicity by suppressing ROS-driven apoptosis.
Absolute Event Rate: 0% vs 0%
Our findings validated the rational design that UA has the potential to mitigate DOX-induced myocardial injury in vitro and in vivo by inhibiting ROS-driven apoptosis, which yields significant insights for combating DOX-mediated myocardial injury.
Song et al. (Wed,) reported a other. Urolithin A mitigated doxorubicin-induced myocardial injury by inhibiting ROS-driven apoptosis both in vitro and in vivo.